430 related articles for article (PubMed ID: 32486355)
1. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?
Plaz Torres MC; Bodini G; Furnari M; Marabotto E; Zentilin P; Strazzabosco M; Giannini EG
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486355
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.
Seif El Dahan K; Daher D; Singal AG
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S207-S219. PubMed ID: 36103899
[TBL] [Abstract][Full Text] [Related]
3. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma.
Said A; Ghufran A
World J Clin Oncol; 2017 Dec; 8(6):429-436. PubMed ID: 29291167
[TBL] [Abstract][Full Text] [Related]
4. An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians.
Cespiati A; Cinque F; Meroni M; Lombardi R; Dongiovanni P; Fracanzani AL
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831120
[TBL] [Abstract][Full Text] [Related]
5. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.
Loomba R; Lim JK; Patton H; El-Serag HB
Gastroenterology; 2020 May; 158(6):1822-1830. PubMed ID: 32006545
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.
Chrysavgis L; Giannakodimos I; Diamantopoulou P; Cholongitas E
World J Gastroenterol; 2022 Jan; 28(3):310-331. PubMed ID: 35110952
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and management issues of NAFLD-related HCC: what we know so far.
Pugliese N; Alfarone L; Arcari I; Giugliano S; Parigi TL; Rescigno M; Lleo A; Aghemo A
Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):31-43. PubMed ID: 36576057
[TBL] [Abstract][Full Text] [Related]
8. Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study.
Prabhakar T; Kaushal K; Prasad M; Gupta E; Sood A; Jain AK; Shukla A; Goel A; Duseja A; Saraya A; Shah S; Kumar G; Sarin SK
Hepatol Int; 2023 Jun; 17(3):745-752. PubMed ID: 36940070
[TBL] [Abstract][Full Text] [Related]
9. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians.
Geh D; Manas DM; Reeves HL
Hepatobiliary Surg Nutr; 2021 Jan; 10(1):59-75. PubMed ID: 33575290
[TBL] [Abstract][Full Text] [Related]
11. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
Tokushige K; Hashimoto E; Kodama K
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges.
Berkan-Kawińska A; Piekarska A
Curr Med Res Opin; 2020 Feb; 36(2):235-243. PubMed ID: 31631714
[No Abstract] [Full Text] [Related]
13. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease.
Than NN; Ghazanfar A; Hodson J; Tehami N; Coldham C; Mergental H; Manas D; Shah T; Newsome PN; Reeves H; Shetty S
QJM; 2017 Feb; 110(2):73-81. PubMed ID: 27634970
[TBL] [Abstract][Full Text] [Related]
14. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
Bertot LC; Adams LA
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
Meringer H; Shibolet O; Deutsch L
World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease.
Tovoli F; Ferri S; Piscaglia F
Curr Pharm Des; 2020; 26(32):3909-3914. PubMed ID: 32348210
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and risk-stratification of NAFLD-associated HCC.
Ioannou GN
J Hepatol; 2021 Dec; 75(6):1476-1484. PubMed ID: 34453963
[TBL] [Abstract][Full Text] [Related]
19. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease.
Lin BZ; Lin TJ; Lin CL; Liao LY; Chang TA; Lu BJ; Chen KY
J Chin Med Assoc; 2021 Jun; 84(6):606-613. PubMed ID: 33871391
[TBL] [Abstract][Full Text] [Related]
20. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
